Among all patients followed for 30-day survival, survivors had significantly higher LRT galectin-3 levels compared to non-survivors (Fig. 6a), and this difference was driven mostly by patients with ARDS (Fig. 6b). The gene discussed is LGALS3; the disease is acute respiratory distress syndrome.